test

An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia

Conditions

Leukemia, not otherwise specified | Myeloid and Monocytic Leukemia

What is the purpose of this trial?

The primary objective is to investigate the maximum tolerated dose (MTD), safety and efficacy of volasertib in combination with decitabine in patients with acute myeloid leukaemia (AML).


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Boehringer Ingelheim Pharmaceuticals, Inc.
Dates:
06/05/2014
Last Updated:
Study HIC#:
1311013040